Pfizer Inc. Press Releases https://investors.pfizer.com/generated by Q4Fri, 24 Apr 2026 16:42:09 -0400Copyright Q4 Inc. All rights reserved.Pfizer Declares Second-Quarter 2026 Dividendd68d7a88-e6b6-43a4-899a-06d1a2bb9c86https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Declares-Second-Quarter-2026-Dividend/default.aspxWed, 22 Apr 2026 16:45:00 -0400Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 20266849236f-74e4-4c17-82d7-31b4c19b9052https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Showcases-Oncology-Innovation-and-Next-Generation-Pipeline-at-ASCO-2026/default.aspxTue, 21 Apr 2026 11:51:00 -0400U.S. FDA Grants Priority Review to sBLA for PADCEV + Keytruda as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility3cead915-bdd3-4e5f-b1cf-a1256f96a8echttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/U-S--FDA-Grants-Priority-Review-to-sBLA-for-PADCEV--Keytruda-as-Perioperative-Treatment-for-Muscle-Invasive-Bladder-Cancer-Regardless-of-Cisplatin-Eligibility-2026--aYF8zy9gB/default.aspxMon, 20 Apr 2026 06:45:00 -0400Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders394ebd36-0990-4cc9-8c16-9180ca1079f4https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Shareholders-to-View-and-Listen-to-Webcast-of-April-23-Virtual-2026-Annual-Meeting-of-Shareholders/default.aspxThu, 09 Apr 2026 10:00:00 -0400Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts3c81e691-874d-40e2-9cb9-0916d51ceaffhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Invites-Public-to-View-and-Listen-to-Webcast-of-May-5-Conference-Call-with-Analysts/default.aspxTue, 24 Mar 2026 10:00:00 -0400Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Triald706e687-95b3-4ca8-9233-a35cb6fff2dfhttps://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-and-Valneva-Announce-Lyme-Disease-Vaccine-Candidate-Demonstrates-Strong-Efficacy-in-Phase-3-VALOR-Trial/default.aspxMon, 23 Mar 2026 06:45:00 -0400Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC081be1ac-b071-4f66-8517-a56200fa3744https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Recommends-Shareholders-Reject-the-Mini-Tender-Offer-by-Tutanota-LLC/default.aspxFri, 20 Mar 2026 16:30:00 -0400TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancerbc26d103-3a70-4ac6-911a-1244f51fb821https://investors.pfizer.com/Investors/news-events/News/news-details/2026/TALZENNA-Plus-XTANDI-Significantly-Improves-Radiographic-Progression-Free-Survival-in-Metastatic-Prostate-Cancer/default.aspxThu, 19 Mar 2026 06:45:00 -0400Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer4c3284b7-cc15-426f-97ee-ae9ea770cba5https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizer-Announces-Positive-Topline-Phase-2-Results-for-Next-Generation-CDK4-Inhibitor-Atirmociclib-in-Second-Line-Metastatic-Breast-Cancer/default.aspxTue, 17 Mar 2026 06:45:00 -0400Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis7c2bc3b7-8434-423e-a3e1-93b94a35eb35https://investors.pfizer.com/Investors/news-events/News/news-details/2026/Pfizers-Phase-2-Study-of-Trispecific-Antibody-Positive-in-Moderate-to-Severe-Atopic-Dermatitis/default.aspxMon, 09 Mar 2026 06:45:00 -0400